I suppose it should come as no great surprise to us that, according to forecasts by Decision Resources, a well known analytic and information company in the healthcare sector, drugs produced for the treatment of back pain and arthritis related pain will continue to be the most lucrative sector of the overall market for chronic pain treatment up to at least 2020.
Lynne Taylor reports on the forecast on the pharmatimes.com website, and it make interesting reading. It also says that the market will remain at a stable £20 billion a year. Not a bad business to be in.
An interesting development is the response of the pharmaceutical companies to the growing problem of prescription opioid abuse. They are experimenting with incorporating abuse deterrent ingredients into their newer formulations.
To read more use this link.
No comments:
Post a Comment